Moomoo AIのまとめ
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to...Show More
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to a higher average principal balance of convertible notes. Novo Integrated Sciences also highlighted business developments such as the launch of MiTelemed+, the expansion of its healthcare services, and the development of health and wellness products. Looking ahead, the company plans to continue focusing on its three primary pillars: service networks, interconnected technology, and health and wellness products, to drive future growth.
Novo Integrated Sciencesは、2024年5月31日に終了した四半期の収益が315万1851ドルで、前年同期の329万2933ドルからわずかに減少しました。同社の営業損失は、主に営業費用の増加とデリバティブ負債の公正価値変動による大きな損失の影響で、前年同期の143万418ドルから252万203ドルに拡大しました。当期の純損失は、為替取引の損失やデリバティブ負債の影響も大きく、前年同期の149万7330ドルに比べて大幅な1374万1903ドルとなりました。九ヶ月間の収益は10%増の1,021万3661ドルとなりましたが、純損失は1005万4098ドルから2116万8374ド...すべて展開
Novo Integrated Sciencesは、2024年5月31日に終了した四半期の収益が315万1851ドルで、前年同期の329万2933ドルからわずかに減少しました。同社の営業損失は、主に営業費用の増加とデリバティブ負債の公正価値変動による大きな損失の影響で、前年同期の143万418ドルから252万203ドルに拡大しました。当期の純損失は、為替取引の損失やデリバティブ負債の影響も大きく、前年同期の149万7330ドルに比べて大幅な1374万1903ドルとなりました。九ヶ月間の収益は10%増の1,021万3661ドルとなりましたが、純損失は1005万4098ドルから2116万8374ドルに増加しました。同社の財務パフォーマンスは、製品コストの変化、高い運営コスト、変換可能ノートの平均元本残高の増加による高い利息費用など、様々な要因によって影響を受けました。Novo Integrated Sciencesは、MiTelemed+のローンチ、ヘルスケアサービスの拡大、ヘルス＆ウェルネス製品の開発など、事業展開の面でも注目されました。今後も同社は、サービスネットワーク、相互接続技術、ヘルス＆ウェルネス製品の3つの主要柱に焦点を当て、将来の成長を推進する計画です。
役に立った
役に立たない
